Schedule 13D ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2017-11-06

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
7.2000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001144204-18-014661
Form type
SC 13D
Filer
Atlas Venture Fund X, L.P.
CIK
CIK 1628098
Filed
Mar 14, 2018
Reporting period
Nov 06, 2017
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub